Tetraphase Pharmaceuticals Inc (TTPH) was Reiterated by Wedbush to “Outperform” while Lowering the Price Target of the company shares to $ 4 from a previous price target of $8 . Wedbush advised their investors in a research report released on May 13, 2016.
On the company’s financial health, Tetraphase Pharmaceuticals Inc reported $-0.50 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on Feb 23, 2016. Analyst had a consensus of $-0.42. The company had revenue of $2.50 million for the quarter, compared to analysts expectations of $3.34 million. The company’s revenue was down -19.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.69 EPS.
Tetraphase Pharmaceuticals Inc opened for trading at $4.54 and hit $4.73 on the upside on Tuesday, eventually ending the session at $4.63, with a gain of 1.98% or 0.09 points. The heightened volatility saw the trading volume jump to 5,30,778 shares. Company has a market cap of $169 M.
In a different news, on Sep 10, 2015, John Craig Thompson (Chief Operating Officer) sold 10,000 shares at $44.08 per share price. According to the SEC, on Sep 3, 2015, Guy Macdonald (President and Chief Executive) sold 10,000 shares at $41.57 per share price. On Aug 17, 2015, David Charles Lubner (SVP and CFO) sold 9,500 shares at $42.92 per share price, according to the Form-4 filing with the securities and exchange commission.
Tetraphase Pharmaceuticals Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant infections. The Company is engaged in developing its product candidate eravacycline which is a fully synthetic tetracycline derivative as a spectrum intravenous (IV) and an oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections including multidrug-resistant Gram-negative infections. TP-271 is a fully synthetic broad-spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271 the Company has conducted a number of in vitro toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens.